Description: Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Home Page: www.molecularpartners.com
Wagistrasse 14
Schlieren,
8952
Switzerland
Phone:
41 44 755 77 00
Officers
| Name | Title |
|---|---|
| Dr. Patrick Amstutz Ph.D. | Co-Founder, CEO, Member of Management Board & Director |
| Dr. Michael Tobias Stumpp Ph.D. | Co-Founder, Executive VP of Projects & Member of Management Board |
| Mr. Robert Hendriks | Senior VP of Finance |
| Mr. Alexander Zurcher | COO & Member of Management Board |
| Ms. Renate Gloggner | Executive VP of People & Community and Member of Management Board |
| Mr. Daniel Steiner Ph.D. | Senior Vice President of Research & Technology |
| Mr. Seth D. Lewis | Senior Vice President of Investor Relations, Communications & Strategy |
| Mr. Michael Pitzner | General Counsel, Compliance Officer, Senior VP Legal & Business Development |
| Dr. Pamela A. Trail Ph.D. | Strategic Consultant |
| Ms. Anne Goubier D.V.M., Ph.D. | Senior Vice President of Research & Early Development |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2835 |
| Price-to-Sales TTM: | 32.8866 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 167 |